Substance / Medication

Dofetilide

SNOMED 116107002 UMLS C0114771

Overview

Active Ingredient

dofetilide

RxNorm CUI

49247

Labeler: Mayne Pharma Inc.Updated: 2026-02-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Dofetilide capsules are contraindicated in patients with congenital or acquired long QT syndromes. Dofetilide capsules should not be used in patients with a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities). Dofetilide capsules are also contraindi

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Atrial flutter

Conduction disorder of the heart

Atrial fibrillation

Arrhythmia

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Cholesterol

LOINC 2093-3

secondary

C reactive protein

LOINC 30522-7

primary

Research Evidence

Published studies and systematic reviews

Sort:

Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5-mg Capsules After Single-Dose Administration in Healthy Subjects.

VanderLugt James T, Bon Charles, Knuth Dean et al. · Clin Pharmacol Drug Dev · 2018

PMID: 28800211RCT

Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.

Vicente Jose, Johannesen Lars, Mason Jay W et al. · J Am Heart Assoc · 2015

PMID: 25870186RCTFull text (PMC)

Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.

Johannesen L, Vicente J, Mason J W et al. · Clin Pharmacol Ther · 2014

PMID: 25054430RCT

The effect of dofetilide on ventricular defibrillation thresholds.

Simon Ron D B, Sturdivant J Lacy, Leman Robert B et al. · Pacing Clin Electrophysiol · 2009

PMID: 19140909RCT

An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.

McBride Brian F, Min Bokyung, Kluger Jeffrey et al. · Ann Noninvasive Electrocardiol · 2006

PMID: 16630091RCTFull text (PMC)

Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation.

Shamiss Yana, Khaykin Yaariv, Oosthuizen Richard et al. · Europace · 2009

PMID: 19819878Trial

Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.

Mykytsey Andrew, Bauman Jerry L, Razminia Mansour et al. · J Cardiovasc Pharmacol Ther · 2007

PMID: 17495256Trial

The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide.

Brendorp Bente, Elming Hanne, Jun Li et al. · Clin Cardiol · 2003

PMID: 12769249TrialFull text (PMC)

Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study.

Pedersen Ole Dyg, Brendorp Bente, Elming Hanne et al. · Card Electrophysiol Rev · 2003

PMID: 14739717Trial

Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy.

Brendorp B, Torp-Pedersen C, Elming H et al. · Eur Heart J · 2003

PMID: 12590905Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Cardiovascular Disease Physician

Internal Medicine — Cardiovascular Disease

NUCC 207RC0000X

Clinical Cardiac Electrophysiology Physician

Internal Medicine — Clinical Cardiac Electrophysiology

NUCC 207RC0001X

Find a Provider

Health Goals

Goals connected through associated conditions

Improve Heart Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Dofetilide (substance)
SNOMED CT: 116107002
UMLS CUI: C0114771
RxNorm CUI: 49247
Labeler: Mayne Pharma Inc.

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.